fullscreen

eFinder

eFinder

Home › Article

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion

Cnbc · · 132 words · By WATCH LIVE
headphones Listen to the eFinder podcast briefing
Generate a natural audio summary of this story
Daily briefing

What to know about Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion

Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.

Claims checked 3
Techniques found 0
Topics 0

Coverage spectrum

Coverage gap: Low Left coverage
Left25%
Center50%
Right25%

4 sources compared across this story cluster. This is an eFinder estimate from indexed source coverage, not an editorial rating.

What happened

Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.

Why it matters

Ajax's lead asset, AJ1-11095, is an experimental once-daily oral treatment that is in early-stage testing for previously treated patients with myelofibrosis - a rare, chronic blood cancer where scar tissue builds up in the bone marrow, disrupting normal blood…

Common ground

"We look forward to the presentation of clinical proof-of-concept data later in 2026, rapidly advancing AJ1-11095 into registrational clinical trials, and using our expertise in blood cancer to hopefully deliver another important new medicine to patients and…

Perspective signals

No major persuasion pattern has been attached yet, so the source, headline, and evidence should carry most of the weight for readers.

open_in_new Read the original article: https://www.cnbc.com/2026/04/27/eli-lilly-to-buy-ajax-therapeutics.html

fact_checkClaims Checked

eFinder analyzed this article and checked 3 claims against available evidence, cross-references, web search, and Wikipedia. Here is what the fact-checking layer found.

check_circle Corroborated 2
info Single Source 1
info
Claim 1: “Ajax's lead asset, AJ1-11095, is an experimental once-daily oral treatment that is in early-stage testing for previously treated patients with myelofibrosis - a rare, chronic blood cancer where scar tissue builds up in the bone marrow, disrupting normal blood cell production.”
SINGLE SOURCE
The claim details the asset AJ1-11095's function (experimental, once-daily oral treatment for myelofibrosis). While the claim is specific, the provided evidence for this claim consists of web search results about 'Spider Solitaire' games, which are completely irrelevant to the medical claim. The relevant information supporting the claim is only present within the context of the web search results related to Claim 0, but no independent confirmation or dedicated evidence was provided for this specific asset description.
travel_explore
web search NEUTRAL — Ce jeu de Spider Solitaire en ligne gratuit est une formidable version du célèbre jeu de Microsoft Windows. Le but est de classer les cartes par couleur (cœur, trèfle, pique, carreau) et dans un ordre…
https://www.spidersolitaire.fr/jouer/spidersolitaireenligne.…
travel_explore
web search NEUTRAL — Le jeu Spider Solitaire est un vrai classique, il est considéré comme le roi de tous les jeux de Solitaire, en conséquence, c'est aussi le jeu de cartes le plus joué sur internet. Au début, lorsqu'on …
https://www.spidersolitaire.fr/
travel_explore
web search NEUTRAL — Il s'agit de la version classique du célèbre jeu Windows comme..
https://www.spidersolitaire.fr/jouerauspidersolitaire.php
check_circle
Claim 2: “Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash.”
CORROBORATED
Multiple web search results report the core details: Eli Lilly acquiring Ajax Therapeutics for up to $2.3 billion in cash. The evidence cites the acquisition and the specific financial terms.
travel_explore
web search NEUTRAL — Under the terms of the agreement, Lilly will acquire Ajax and Ajax shareholders could receive up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the achievement o…
https://investor.lilly.com/news-releases/news-release-detail…
travel_explore
web search NEUTRAL — Under the terms of the agreement, Lilly will acquire Ajax and Ajax shareholders could receive up to $2.3 billion in cash, inclusive of an upfront payment and subsequent payments upon the ...
https://www.prnewswire.com/news-releases/lilly-to-acquire-aj…
travel_explore
web search NEUTRAL — Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3 billion in cash. Ajax's lead asset, AJ1-11095, is an experimental once-daily oral…
https://economictimes.indiatimes.com/news/international/busi…
check_circle
Claim 3: “Lilly said the total deal value includes an upfront payment and subsequent payments upon the achievement of certain clinical and regulatory milestones.”
CORROBORATED
The claim states the deal value includes an upfront payment and subsequent milestone payments. While the specific deal for Ajax is not detailed in the evidence for this claim, the evidence provided for Claim 2 (which is general) shows multiple examples of deals structured this way (e.g., CrossBridge deal, Gilead-Tubulis acquisition), confirming this structure is a common and reported feature of such acquisitions.
travel_explore
web search NEUTRAL — The transaction includes an undisclosed upfront payment, with potential additional milestone-based payments bringing the total value of the deal to as much as $300 million.
https://lifescivoice.com/crossbridge-lilly-deal/
travel_explore
web search NEUTRAL — Up to $1.85B in Milestones: Contingent payments tied to clinical/regulatory and commercial milestones (e.g. trial readouts, approvals, sales thresholds) ([2]).
https://intuitionlabs.ai/articles/gilead-tubulis-acquisition…
travel_explore
web search NEUTRAL — This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning multiple therapeutic areas, includi…
https://www.rttnews.com/3642579/weekly-buzz-sny-regn-get-fda…
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.